GE HealthCare Technologies Inc. (GEHC) Stock

About GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

GE HealthCare Technologies Inc. is led by CEO Peter J. Arduini, employs 53,000 people, headquartered in Chicago, US, publicly traded since 2022.

GE HealthCare Technologies Inc. (GEHC) stock trades at $70.31 with a market capitalization of $31.76B. The stock is valued at a price-to-earnings (P/E) ratio of 14.94, price-to-book of 2.74, price-to-sales of 1.40. Over the past 52 weeks the stock has ranged between $58.75 and $89.77, and currently trades 21.7% below its 52-week high. It pays a dividend yielding 0.22%.

On profitability, GE HealthCare Technologies Inc. generates a return on equity (ROE) of 19.46%, above the typical market average, return on capital employed of 26.06%, an operating margin of 12.46%, a net profit margin of 7.54%.

In its most recent fiscal year, GE HealthCare Technologies Inc. reported annual revenue of $20.6B, net profit of $2.1B, revenue has compounded at 3.7% a year over the last five years, profit at -31.5% a year.

The balance sheet shows a debt-to-equity ratio of 0.99, a current ratio of 1.18, total assets of $36.9B, $4.5B in cash and equivalents.

GEHC has an average daily trading volume of 5,667,119 shares, a beta of 0.86.

Official website: www.gehealthcare.com